Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,24469600,half-life,"At fasting state, amisulpride reached the first peak (37.1 ± 13.3 ng/ml) at ~2.3 h, and decreased down to 19.4 ± 4.3 ng/ml until 3.5 h, and then again went up to the second peak (25.3 ± 5.8 ng/ml) at 5 h followed by a slow decay with 10.6 h of half-life.",Prandial effect on the systemic exposure of amisulpride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,10.6,37200,DB06288,Amisulpride
,24469600,maximum concentration,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),[ng] / [ml],56.0,37201,DB06288,Amisulpride
,24469600,time to peak,"The maximum concentration of amisulpride (56.0 ± 12.7 ng/ml) was increased by a 1.5-fold compared with that under fasting (p > 0.05), and the time to peak shortened a little (1.7 ± 0.6 h).",Prandial effect on the systemic exposure of amisulpride. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24469600/),h,1.7,37202,DB06288,Amisulpride
,31975684,peak plasma concentration,"The peak plasma concentration of pure drug was 30.05 ± 1.3 ng/ml (Cmax) at 60 ± 3 min, whereas with the market product the value was 54.85 ± 1.2 ng/ml at 40 ± 1 min and with AMS-HPβCD inclusion complex the value was 79.01 ± 1.5 ng/ml.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),[ng] / [ml],30.05,46276,DB06288,Amisulpride
,31975684,peak plasma concentration,"The peak plasma concentration of pure drug was 30.05 ± 1.3 ng/ml (Cmax) at 60 ± 3 min, whereas with the market product the value was 54.85 ± 1.2 ng/ml at 40 ± 1 min and with AMS-HPβCD inclusion complex the value was 79.01 ± 1.5 ng/ml.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),[ng] / [ml],54.85,46277,DB06288,Amisulpride
,31975684,peak plasma concentration,"The peak plasma concentration of pure drug was 30.05 ± 1.3 ng/ml (Cmax) at 60 ± 3 min, whereas with the market product the value was 54.85 ± 1.2 ng/ml at 40 ± 1 min and with AMS-HPβCD inclusion complex the value was 79.01 ± 1.5 ng/ml.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),[ng] / [ml],79.01,46278,DB06288,Amisulpride
,31975684,Cmax,"The peak plasma concentration of pure drug was 30.05 ± 1.3 ng/ml (Cmax) at 60 ± 3 min, whereas with the market product the value was 54.85 ± 1.2 ng/ml at 40 ± 1 min and with AMS-HPβCD inclusion complex the value was 79.01 ± 1.5 ng/ml.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),[ng] / [ml],79.01,46279,DB06288,Amisulpride
,31975684,AUCtot,"The AUCtot of the pure drug was 2980.34±3.6, the market product was 7238.73±2.9 and of the inclusion complex was 11871.1±2.8.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),,2980.34,46280,DB06288,Amisulpride
,31975684,AUCtot,"The AUCtot of the pure drug was 2980.34±3.6, the market product was 7238.73±2.9 and of the inclusion complex was 11871.1±2.8.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),,7238.73,46281,DB06288,Amisulpride
,31975684,AUCtot,"The AUCtot of the pure drug was 2980.34±3.6, the market product was 7238.73±2.9 and of the inclusion complex was 11871.1±2.8.",Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),,11871.1,46282,DB06288,Amisulpride
,31975684,oral bioavailability,The oral bioavailability of AMS was improved from 48% to 78%.,Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),%,48,46283,DB06288,Amisulpride
,31975684,oral bioavailability,The oral bioavailability of AMS was improved from 48% to 78%.,Oral Bioavailability Enhancement of Amisulpride: Complexation and its Pharmacokinetics and Pharmacodynamics Evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31975684/),%,78,46284,DB06288,Amisulpride
,8852049,limit of quantitation (LOQ),The limit of quantitation (LOQ) in human plasma is 2.5 ng ml-1 for both S-(-)- and R-(+)-amisulpride isomers with both detection methods.,"Stereospecific determination of amisulpride, a new benzamide derivative, in human plasma and urine by automated solid-phase extraction and liquid chromatography on a chiral column. application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8852049/),[ng] / [ml],2.5,57548,DB06288,Amisulpride
,21886905,flow-rate,"Chromatographic separation was performed on Zorbax Bonus-RP C18, 4.6 × 75 mm, 3.5 μm column with an isocratic mobile phase composed of 0.2% formic acid:methanol (35:65 v/v), at a flow-rate of 0.5 mL/min.",Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21886905/),[ml] / [min],0.5,73760,DB06288,Amisulpride
,21886905,m/,"Amisulpride, Amisulpride-d(5) was detected at m/z 370.1→242.1 and 375.1→242.1.",Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21886905/),,370.1,73761,DB06288,Amisulpride
,21886905,m/,"Amisulpride, Amisulpride-d(5) was detected at m/z 370.1→242.1 and 375.1→242.1.",Development and validation of amisulpride in human plasma by HPLC coupled with tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21886905/),,375.1,73762,DB06288,Amisulpride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.0,84478,DB06288,Amisulpride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,5,84479,DB06288,Amisulpride
,27618796,ΔΔQTcF,"The therapeutic dose of 5 mg amisulpride was associated with a slight, transient increase in mean ΔΔQTcF, from 2.0 ms prior to dosing to a peak of 5 ms (90% CI: 2.8, 7.1 ms) at 8 min, decreasing to 2.1 ms at 30 min after dosing.",Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27618796/),ms,2.1,84480,DB06288,Amisulpride
,30652198,oral bioavailability,"Amisulpride (AMS), a second generation antipsychotic, suffers from low oral bioavailability (48%).","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),%,48,96803,DB06288,Amisulpride
,30652198,entrapment efficiency,"The average entrapment efficiency, particle size, polydispersity index, and zeta potential of the prepared formulations ranged from 29.01 to 69.06%, 184.9 to 708.75 nm, 0.21 to 0.59, and - 21 to - 33.55 mV, respectively.","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),%,29,96804,DB06288,Amisulpride
,30652198,particle size,"The average entrapment efficiency, particle size, polydispersity index, and zeta potential of the prepared formulations ranged from 29.01 to 69.06%, 184.9 to 708.75 nm, 0.21 to 0.59, and - 21 to - 33.55 mV, respectively.","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),nm,184.9 to 708.75,96805,DB06288,Amisulpride
,30652198,particle size,"The average entrapment efficiency, particle size, polydispersity index, and zeta potential of the prepared formulations ranged from 29.01 to 69.06%, 184.9 to 708.75 nm, 0.21 to 0.59, and - 21 to - 33.55 mV, respectively.","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),m,0,96806,DB06288,Amisulpride
,30652198,polydispersity index,"The average entrapment efficiency, particle size, polydispersity index, and zeta potential of the prepared formulations ranged from 29.01 to 69.06%, 184.9 to 708.75 nm, 0.21 to 0.59, and - 21 to - 33.55 mV, respectively.","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),m,0,96807,DB06288,Amisulpride
,30652198,zeta potential,"The average entrapment efficiency, particle size, polydispersity index, and zeta potential of the prepared formulations ranged from 29.01 to 69.06%, 184.9 to 708.75 nm, 0.21 to 0.59, and - 21 to - 33.55 mV, respectively.","Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),m,0,96808,DB06288,Amisulpride
,30652198,relative bioavailability,The relative bioavailability of AMS-NLCs capsules was found to be 252.78%.,"Enhanced Oral Absorption of Amisulpride Via a Nanostructured Lipid Carrier-Based Capsules: Development, Optimization Applying the Desirability Function Approach and In Vivo Pharmacokinetic Study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30652198/),%,252.78,96809,DB06288,Amisulpride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,2,98969,DB06288,Amisulpride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,1.5,98970,DB06288,Amisulpride
,4049901,half-lives,"Mean blood levels of total 14C peaked at 0.4-1.1 h and declined with half-lives of 2, 1.5 and 3 h in rat, rabbit and dog, respectively.","Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,3,98971,DB06288,Amisulpride
,4049901,half-life,In man mean serum levels of unchanged drug attained a peak at 1.5 h and were eliminated with a half-life of 3.6 h.,"Absorption, distribution and excretion of sultopride in man and several animal species. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4049901/),h,3.6,98972,DB06288,Amisulpride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),[ng] / [ml],71,112312,DB06288,Amisulpride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,65,112313,DB06288,Amisulpride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,67,112314,DB06288,Amisulpride
,28334978,steady state blood levels,"Average steady state blood levels were low (71 ± 30 ng/ml), and associated with high D2/3 occupancies (65 ± 8%, caudate; 67 ± 11%, thalamus; 52 ± 11%, putamen).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,52,112315,DB06288,Amisulpride
,28334978,D2/3,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112316,DB06288,Amisulpride
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,43,112317,DB06288,Amisulpride
,28334978,occupancies,"Antipsychotic clinical response occurred at a threshold concentration of 20 ng/ml and D2/3 occupancies of 43% (caudate), 25% (putamen), 43% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),%,25,112318,DB06288,Amisulpride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,61,112319,DB06288,Amisulpride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,49,112320,DB06288,Amisulpride
,28334978,o,"Extrapyramidal side effects (n = 7) emerged at a threshold concentration of 60 ng/ml, and D2/3 occupancies of 61% (caudate), 49% (putamen) and 69% (thalamus).",Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28334978/),,69,112321,DB06288,Amisulpride
,16252067,area under concentration-time curve,"Accordingly, the area under concentration-time curve in serum and brain was higher in CsA co-treated rats (13.5 vs.",Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16252067/),,13.5,116658,DB06288,Amisulpride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],19.5,119038,DB06288,Amisulpride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],"5,188",119039,DB06288,Amisulpride
,20925494,milk:plasma distribution ratio,"Transfer of amisulpride into milk was high, with a milk:plasma distribution ratio of 19.5 (5,188 μg/L in milk and 266 μg/L in plasma).",Estimation of rac-amisulpride transfer into milk and of infant dose via milk during its use in a lactating woman with bipolar disorder and schizophrenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20925494/),[μg] / [l],266,119040,DB06288,Amisulpride
,31900797,pKa,"Amisulpride (AMS) is atypical antipsychotic with a weak basic nature (pKa 9.37), which results in low solubility in the high pH of the intestine.","Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900797/),,9.37,120157,DB06288,Amisulpride
,31900797,oral bioavailability,Both factors lead to its low oral bioavailability (48%).,"Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900797/),%,48,120158,DB06288,Amisulpride
≥,31900797,similarity factor (f2),All formulae with acidic pH modifier had similarity factor (f2) ≥ 50 proving the pH independent release of AMS.,"Microenvironmental pH-modified Amisulpride-Labrasol matrix tablets: development, optimization and in vivo pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900797/),,50,120159,DB06288,Amisulpride
,16386474,peak plasma concentration (C(max)),A peak plasma concentration (C(max)) of 522.58 ng/ml was achieved after 3.55 h (t(max)).,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ng] / [ml],522.58,139920,DB06288,Amisulpride
,16386474,t(max),A peak plasma concentration (C(max)) of 522.58 ng/ml was achieved after 3.55 h (t(max)).,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),h,3.55,139921,DB06288,Amisulpride
,16386474,areas under the plasma concentration-time curve (AUC),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3405.35,139922,DB06288,Amisulpride
,16386474,AUC(0-infinity),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3405.35,139923,DB06288,Amisulpride
,16386474,AUC(0-tlast),Corresponding values of areas under the plasma concentration-time curve (AUC) of 3405.35 ngh/ml (AUC(0-infinity)) and 3306.54 ngh/ml (AUC(0-tlast)) were obtained.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),[ngh] / [ml],3306.54,139924,DB06288,Amisulpride
,16386474,terminal plasma elimination half-life (t(1/2)),The terminal plasma elimination half-life (t(1/2)) was 10.36 h.,Selective and sensitive determination of amisulpride in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionisation and multiple reaction monitoring. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386474/),h,10.36,139925,DB06288,Amisulpride
,12404702,bioavailability,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,48,142126,DB06288,Amisulpride
,12404702,protein binding,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),%,17,142127,DB06288,Amisulpride
,12404702,elimination half-life,"Amisulpride shows linear pharmacokinetics, a bioavailability of 48%, low protein binding (17%) and an elimination half-life of approximately 12 h.","A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404702/),h,12,142128,DB06288,Amisulpride
,16324716,plasma levels,Patients with EPS (14.6%) had significantly (P<0.05) higher amisulpride plasma levels (377+/-290 ng/ml) than patients without EPS (305+/-274 ng/ml) despite similar doses in both groups (595+/-266 vs. 594+/-246 mg).,Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16324716/),[ng] / [ml],377,146373,DB06288,Amisulpride
,16324716,plasma levels,Patients with EPS (14.6%) had significantly (P<0.05) higher amisulpride plasma levels (377+/-290 ng/ml) than patients without EPS (305+/-274 ng/ml) despite similar doses in both groups (595+/-266 vs. 594+/-246 mg).,Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16324716/),[ng] / [ml],305,146374,DB06288,Amisulpride
,4030988,detection limit,The detection limit in plasma and RBC was 10 ng/ml for sulpiride and 15 ng/ml for sultopride.,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),[ng] / [ml],10,164665,DB06288,Amisulpride
,4030988,detection limit,The detection limit in plasma and RBC was 10 ng/ml for sulpiride and 15 ng/ml for sultopride.,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),[ng] / [ml],15,164666,DB06288,Amisulpride
,4030988,Half-lives,Half-lives determined from either plasma or RBC concentrations were similar (7 h for sulpiride and 5 h for sultopride).,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),h,7,164667,DB06288,Amisulpride
,4030988,Half-lives,Half-lives determined from either plasma or RBC concentrations were similar (7 h for sulpiride and 5 h for sultopride).,[Determination of sulpiride and sultopride by high-performance liquid chromatography for pharmacokinetic studies]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4030988/),h,5,164668,DB06288,Amisulpride
,3667781,detection limit,"The detector response is linear from 25 to 10,000 ng/ml, and the detection limit is 3 ng/ml for alizapride and 10 ng/ml for metoclopramide.",Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667781/),[ng] / [ml],3,185208,DB06288,Amisulpride
,3667781,detection limit,"The detector response is linear from 25 to 10,000 ng/ml, and the detection limit is 3 ng/ml for alizapride and 10 ng/ml for metoclopramide.",Liquid chromatographic analysis of alizapride and metoclopramide in human plasma and urine using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3667781/),[ng] / [ml],10,185209,DB06288,Amisulpride
,28793958,AUC<sub>0-tlast</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup>],"4,767.2",190834,DB06288,Amisulpride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup>],"4,856.3",190835,DB06288,Amisulpride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup],"4,891.7",190836,DB06288,Amisulpride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[h·ng] / [ml<sup>·sup],"5,043.2",190837,DB06288,Amisulpride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],584.7,190838,DB06288,Amisulpride
,28793958,AUC<sub>0-∞</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],586.3,190839,DB06288,Amisulpride
,28793958,C<sub>max</sub>,"The pharmacokinetic parameters of AUC<sub>0-tlast</sub>, AUC<sub>0-∞</sub>, and C<sub>max</sub> for the 20 subjects after a single oral dose of the trial preparation or the reference preparation were 4,767.2 and 4,856.3 ng×h×mL<sup>-1</sup>; 4,891.7 and 5,043.2 ng×h×mL<sup>-1</sup>; 584.7 and 586.3 ng×mL<sup>-1</sup>, respectively.",Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),[ng] / [ml<sup>·sup],586.3,190840,DB06288,Amisulpride
,28793958,relative bioavailability,The relative bioavailability was 98.9 ± 14.5%.,Pharmacokinetics and relative bioavailability of a generic amisulpride tablet in healthy Chinese volunteers . ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28793958/),%,98.9,190841,DB06288,Amisulpride
,7337503,apparent half life,"Serum sultopride levels reached peak 1 hr after the administration and declined with an apparent half life of 3.5 hr, while serum sulpiride levels increased gradually and the high serum level at 2 hr remained for up to 6 hr.",Development of radioimmunoassay for sultopride and sulpiride. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7337503/),h,3.5,197324,DB06288,Amisulpride
,28643852,occupancy,"In three participants, imaged during optimal treatment (50 mg/day; 41-70 ng/ml), caudate occupancy was 44-59% (58-74% in AD across a comparable Caverage).",Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643852/),%,44-59,204098,DB06288,Amisulpride
,28643852,occupancy,"In three participants, imaged during optimal treatment (50 mg/day; 41-70 ng/ml), caudate occupancy was 44-59% (58-74% in AD across a comparable Caverage).",Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28643852/),%,58-74,204099,DB06288,Amisulpride
,18562411,C/D ratios,"Mean amisulpride doses (574 +/- 269 mg/day), plasma levels (304 +/- 274 ng/mL), dose-corrected amisulpride plasma levels (C/D ratios, 0.52 +/- 0.41 ng/mL:mg), clinical response (at least moderate improvement, 71.6%), and side effects (any side effect, 32.2%; extrapyramidal symptoms, 14.9%) were comparable between age groups (P > 0.25).",Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18562411/),[ng] / [ml:mg],0.52,207735,DB06288,Amisulpride
,18655221,run time,A run time of 2.0 min for each sample made it possible to analyze more than 275 human plasma samples per day.,Liquid chromatography tandem mass spectrometry method for the quantification of amisulpride with LLOQ of 100 pg/mL using 100 microL of plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18655221/),min,2.0,211122,DB06288,Amisulpride
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.41,212065,DB06288,Amisulpride
,16555163,plasma levels,"However, dose-corrected steady-state amisulpride plasma levels (men 0.41 +/- 0.31 ng/mL/mg; women 0.60 +/- 0.39 ng/mL/mg; P = 0.007) were significantly higher in female patients even after age adjustment.",Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16555163/),[ng] / [mg·ml],0.60,212066,DB06288,Amisulpride
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],64.1,221765,DB06288,Amisulpride
,9754984,Cmax,"The mean Cmax of the racemate amisulpride in elderly people was 64.1+/-6.7 ng ml(-1), and was not different from the value of 56+/-4.1 ng ml(-1) in young subjects.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),[ng] / [ml],56,221766,DB06288,Amisulpride
,9754984,t1/2,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),h,15.6,221767,DB06288,Amisulpride
,9754984,AUC,"As with the Cmax, the mean values of t1/2 and AUC in elderly people (15.6+/-1.3 h and 667+/-51 ng.",Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9754984/),ng,667,221768,DB06288,Amisulpride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.94,250000,DB06288,Amisulpride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.62,250001,DB06288,Amisulpride
,8911882,blood ethanol,"Mean blood ethanol was 0.94, 0.62 and 0.26 g.1(-1) at the three test times.",Single oral doses of amisulpride do not enhance the effects of alcohol on the performance and memory of healthy subjects. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8911882/),g,0.26,250002,DB06288,Amisulpride
